Patent: 10,011,660
✉ Email this page to a colleague
Summary for Patent: 10,011,660
| Title: | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| Abstract: | Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide. |
| Inventor(s): | Tsui; Ping (Gaithersburg, MD), Borrok, II; Martin (Gaithersburg, MD), Dall\'Acqua; William (Gaithersburg, MD) |
| Assignee: | MedImmune, LLC (Gaithersburg, MD) |
| Application Number: | 14/397,958 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,011,660
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Csl Behring Ag | CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN | immune globulin intravenous (human) | For Injection | 102367 | July 27, 2000 | ⤷ Start Trial | 2033-04-17 |
| Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | July 26, 2007 | ⤷ Start Trial | 2033-04-17 |
| Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | October 02, 2009 | ⤷ Start Trial | 2033-04-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
